|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.405 EUR | -0.71% |
|
-2.43% | -7.87% |
| May. 15 | Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS | CI |
| May. 14 | Medigene Ag Maintains Earnings Guidance for 2024 | CI |
Medigene AG maintains revenue guidance for the fiscal year 2022. For the period, the company continues to expect revenues of EUR 23 million to EUR 28 million.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.87% | 37.78M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
MEDIGENE AG 